Last reviewed · How we verify
traditional IVM system
traditional IVM system is a Glutamate-gated chloride channel agonist Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for River blindness, Lymphatic filariasis. Also known as: sage.
Ivermectin acts as a glutamate-gated chloride channel agonist.
A traditional IVM (In Vitro Maturation) system is a method used in fertility treatments, specifically studied for conditions such as Diabetic Retinopathy, Polycystic Ovary Syndrome, and Infertility. It is one of the interventions used in clinical trials, alongside other methods like intracytoplasmic sperm injection (ICSI), to assist with fertility treatments.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | traditional IVM system |
|---|---|
| Also known as | sage |
| Sponsor | Sun Yat-sen University |
| Drug class | Glutamate-gated chloride channel agonist |
| Target | Glutamate-gated chloride channel |
| Modality | Small molecule |
| Therapeutic area | Parasitology |
| Phase | Phase 3 |
Mechanism of action
This results in increased chloride ion influx into the neuron, leading to hyperpolarization and eventual paralysis and death of the parasite.
Approved indications
- River blindness
- Lymphatic filariasis
Common side effects
- Hypersensitivity reactions
- Neurological effects
Key clinical trials
- The Sensitivity of Traditional Chinese Medical Diagnostic Tools for Diabetic Retinopathy Diabetic retinopathy-a Pilot Study
- New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- traditional IVM system CI brief — competitive landscape report
- traditional IVM system updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about traditional IVM system
What is traditional IVM system?
How does traditional IVM system work?
What is traditional IVM system used for?
Who makes traditional IVM system?
Is traditional IVM system also known as anything else?
What drug class is traditional IVM system in?
What development phase is traditional IVM system in?
What are the side effects of traditional IVM system?
What does traditional IVM system target?
Related
- Drug class: All Glutamate-gated chloride channel agonist drugs
- Target: All drugs targeting Glutamate-gated chloride channel
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Parasitology
- Indication: Drugs for River blindness
- Indication: Drugs for Lymphatic filariasis
- Also known as: sage
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing